135 related articles for article (PubMed ID: 12573343)
1. Rituximab for BCL-2-positive cancers.
Boughton B
Lancet Oncol; 2003 Feb; 4(2):69. PubMed ID: 12573343
[No Abstract] [Full Text] [Related]
2. CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).
Yokose N; Shioi Y; Sugisaki Y; Ohaki Y; Ogata K; Dan K
Leuk Lymphoma; 2006 Jul; 47(7):1415-7. PubMed ID: 16923582
[No Abstract] [Full Text] [Related]
3. Rituximab for bone lymphoma.
Savage DG; Staron R
Ann Intern Med; 2001 Jun; 134(12):1156-7. PubMed ID: 11412072
[No Abstract] [Full Text] [Related]
4. Rituximab for early-stage diffuse large-B-cell lymphoma.
Friedberg JW
Lancet Oncol; 2006 May; 7(5):357-9. PubMed ID: 16648037
[No Abstract] [Full Text] [Related]
5. [Relationship between clinopathological features and outcome of rituximab treatment for diffuse large B-cell lymphoma].
Zhang HY; Guan ZZ; Wang B; Huang HQ; Xia ZJ; Lin TY
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):381-4. PubMed ID: 18953841
[TBL] [Abstract][Full Text] [Related]
6. [Primary diffuse large B-cell lymphoma in uterine corpus: report of a case].
Dong W; Cao L; Wang DS
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):270-2. PubMed ID: 21616007
[No Abstract] [Full Text] [Related]
7. Rituximab in diffuse large B-cell lymphoma.
Coiffier B
Clin Adv Hematol Oncol; 2004 Mar; 2(3):156-7. PubMed ID: 16166943
[No Abstract] [Full Text] [Related]
8. Durable remission after the administration of rituximab for EBV-negative, diffuse large B-cell lymphoma following autologous peripheral blood stem cell transplantation for angioimmunoblastic T-cell lymphoma.
Shinohara A; Asai T; Izutsu K; Ota Y; Takeuchi K; Hangaishi A; Kanda Y; Chiba S; Motokura T; Kurokawa M
Leuk Lymphoma; 2007 Feb; 48(2):418-20. PubMed ID: 17325908
[No Abstract] [Full Text] [Related]
9. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab.
Yamagata M; Murohisa T; Tsuchida K; Okamoto Y; Tsunoda S; Nakamura M; Kusano K; Majima Y; Kuniyoshi T; Iijima M; Sugaya H; Hiraishi H
Leuk Lymphoma; 2007 Feb; 48(2):431-3. PubMed ID: 17325912
[No Abstract] [Full Text] [Related]
10. Prognostic significance of the Bcl-2 negative germinal centre in patients with diffuse large B cell lymphoma treated with R-CHOP.
Song MK; Chung JS; Shin DH; Seol YM; Shin HJ; Choi YJ; Cho GJ
Leuk Lymphoma; 2009 Jan; 50(1):54-61. PubMed ID: 19152170
[TBL] [Abstract][Full Text] [Related]
11. Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome.
Sano T; Sakai H; Takimoto K; Ohno H
Int J Clin Oncol; 2007 Feb; 12(1):59-62. PubMed ID: 17380444
[TBL] [Abstract][Full Text] [Related]
12. Intra-vascular large B-cell lymphoma revealed by a nephrotic syndrome: a one year remission induced by a high frequency CHOP and rituximab.
Girard T; Nochy D; Montravers F; Der Sahakian G; Fior R; Galanaud P; Boué F
Leuk Lymphoma; 2004 Aug; 45(8):1703-5. PubMed ID: 15370230
[TBL] [Abstract][Full Text] [Related]
13. Short-term efficacy of rituximab-CHOP and CHOP regimens on two subtypes of diffuse large B-cell lymphoma.
Xia Y; Li ZM; Shi YX; Xia ZJ; Jiang WQ; Huang HQ
Ai Zheng; 2009 Feb; 28(2):146-9. PubMed ID: 19550126
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab.
Uchino K; Sameshima H; Miyamoto T; Iino T; Kato K; Henzan H; Aoki K; Nagafuji K; Gondo H; Harada M
Intern Med; 2004 Feb; 43(2):131-4. PubMed ID: 15005256
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression.
Saito B; Shiozawa E; Yamochi-Onizuka T; Adachi D; Nakamaki T; Tomoyasu S; Omine M; Mitsuya T; Takimoto M; Ota H
Pathol Int; 2004 Sep; 54(9):667-74. PubMed ID: 15363034
[TBL] [Abstract][Full Text] [Related]
17. Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature.
Mian M; Rass C; Hutarew G; Kofler B; Fiegl M; Greil R
Leuk Lymphoma; 2006 Aug; 47(8):1683-5. PubMed ID: 16966286
[No Abstract] [Full Text] [Related]
18. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).
Aboulafia DM
Am J Clin Oncol; 2001 Jun; 24(3):237-40. PubMed ID: 11404492
[TBL] [Abstract][Full Text] [Related]
19. What is the role of rituximab in salvage treatment for patients with diffuse large B-cell lymphoma?
Crump M
Leuk Lymphoma; 2006 Dec; 47(12):2437-9. PubMed ID: 17169786
[No Abstract] [Full Text] [Related]
20. Double-hit lymphomas constitute a highly aggressive subgroup in diffuse large B-cell lymphomas in the era of rituximab.
Kobayashi T; Tsutsumi Y; Sakamoto N; Nagoshi H; Yamamoto-Sugitani M; Shimura Y; Mizutani S; Matsumoto Y; Nishida K; Horiike S; Asano N; Nakamura S; Kuroda J; Taniwaki M
Jpn J Clin Oncol; 2012 Nov; 42(11):1035-42. PubMed ID: 22984125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
